+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  • PDF Icon


  • 68 Pages
  • October 2023
  • Region: Global
  • GlobalData
  • ID: 5908799
The report provides an in-depth assessment of the Myasthenia gravis market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

Myasthenia Gravis (MG) is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In the majority of patients, the disease is initially localized and limited to the eye muscles, causing drooping of the eyelid (ptosis) and double vision (diplopia). This weakness can give patients difficulty controlling eye and eyelid movement, facial expressions, chewing, and talking. In some cases, the disease progressively begins to affect respiratory muscles. MG is considered to be the most common neuromuscular disorder, although it is still classified as a rare disease. The precise etiology of MG is idiopathic, and while factors such as infections are known to increase susceptibility, the specific cause is often indeterminable. The disruption of the normal communication between nerves and muscles at the neuromuscular junction is a key pathological process in MG, which results in impairment of the patient’s ability to engage in voluntary muscle movements.

Key Highlights

Report deliverables include a Pdf and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032


  • Overview of Myasthenia gravis disease, classification of Myasthenia gravis according to the Myasthenia Gravis Foundation of America guideline, etiology, pathophysiology, and epidemiology of Myasthenia gravis
  • Current treatment options including product profiles for Myasthenia gravis marketed in the 7MM.
  • Analysis of unmet needs and R&A strategies within the Myasthenia gravis market.
  • Pipeline analysis including product profiles for leading candidates in the 7MM.
  • Myasthenia gravis market outlook including revenue breakdown by market between the years 2022 and 2032

Reasons to Buy

  • Understand the trends shaping and driving the Myasthenia gravis market
  • Identify the innovative technologies and key players leading the Myasthenia gravis field
  • Recognize gaps and areas of unmet need within the Myasthenia gravis market
  • Determine the current and future outlook for Myasthenia gravis according to key opinion leaders (KOLs)
  • Track Myasthenia gravis sales from 2022-2032

Table of Contents

1. Preface
1.1. Contents
1.2. Related Reports
1.3. Abbreviations
2. Executive Summary
3. Disease Overview
3.1. Overview of Myasthenia Gravis
3.2. Myasthenia Gravis SWOT Analysis
3.3. Antibody Classification of Myasthenia Gravis
3.4. Classification of Myasthenia Gravis
3.5. MGFA Classification of Myasthenia Gravis
4. Epidemiology
4.1. Diagnosed Prevalent Cases of MG
4.2. Age-Specific Trends in Diagnosed Prevalent Cases of MG
4.3. Sex-Specific Diagnosed Prevalent Cases of MG
4.4. Sources and Methodology for MG Prevalence
4.5. Sources and Methodology for MG
5. Current Treatment Options
5.1. Treatment Paradigm
5.2. Current Treatment Options
5.3. Current Treatment Options - KOL Perspective
5.4. Product Profile: Immunosuppressants (Tacrolimus, Cyclosporine, Azathioprine)
5.5. Product Profile: Corticosteroids (Prednisone, Hydrocortisone, Methylprednisone)
5.6. Product Profile: Acetylcholinesterase Inhibitors (Pyridostigmine, Neostigmine, Ambenonium)
5.7. Product Profile: IgG Inhibitors (Vyvgart, Vyvgart Hytrulo, Rystiggo)
5.8. Product Profile: Complement Inhibitors (Soliris, Ultomiris, Zilbrysq)
5.9. Product Profile: Other Classes (Rituxan)
6. Unmet Needs and Opportunities
6.1. Unmet Needs in Myasthenia Gravis
6.2. Cost of Disease Modifying Therapies
6.3. Prognostic Biomarkers
6.4. Public and Physician Awareness
6.5. Frequency of Administration
6.6. Standardization of Classification and Treatment Guidelines
7. R&D Strategies
7.1. Trends in Clinical Trial Design in Myasthenia Gravis
7.2. R&D strategies in Myasthenia Gravis
7.3. Trends in Deal-Making in Myasthenia Gravis
8. Pipeline Assessment
8.1. Myasthenia Gravis Pipeline Overview
8.2. Late-Stage Pipeline Agents for Myasthenia Gravis
8.3. Product Profile: Horizon Therapeutic’s Uplizna (inebilizumab)
8.4. Product Profile: Regeneron’s Pozelimab in Combination with Alnylam’s Cemdisiran
8.5. Product Profile: Roche’s Enspryng (satralizumab)
8.6. Product Profile: Immunovant’s batoclimab
8.7. Product Profile: Alexion’s/AstraZeneca’s gefurulimab
8.8. Product Profile: Janssen’s nipocalimab
9. Market Outlook
9.1. Myasthenia Gravis Market Forecast
9.2. Market Drivers and Barriers
10. Appendix
10.1. Primary Research - KOL Information
10.2. About the Authors
11. Contact the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alexion
  • AstraZeneca
  • Argenx
  • UCB
  • Janssen Pharmaceuticals
  • Horizon Therapeutics Plc
  • Regeneron Pharmaceuticals
  • Chugai Pharmaceutical Co Ltd
  • Hoffmann-La Roche
  • Immunovant Inc
  • Alnylam Pharmaceuticals Inc